Medicare's drug spending now has a ceiling: $2,100, and then nothing
Part D's out-of-pocket cap rose to $2,100 for 2026, and the first ten negotiated drug prices took effect January 1 — Eliquis, Jardiance, Xarelto, Entresto and six more, at 38% to 79% below list.
For most of Part D's history, there was no ceiling. A Medicare enrollee on an expensive drug paid a percentage, and that percentage of a very large number was a very large number, every year, forever. That structural hole is now closed.
In 2026 the annual out-of-pocket cap for covered Part D drugs is $2,100, up from $2,000 in 2025. Once you reach it, you pay nothing for covered prescriptions for the rest of the year. It is the most consequential change to Medicare drug coverage since Part D was created, and a lot of the people it helps most do not know it exists.
- $2,100 — 2026 Part D annual out-of-pocket cap, up from $2,000
- 10 drugs with Medicare-negotiated Maximum Fair Prices effective January 1, 2026
- 38% to 79% — range of discounts off list price
- ~50% — average drop in cost-sharing on the negotiated drugs
- $1.5 billion — CMS estimate of collective enrollee out-of-pocket savings in 2026
(Sources: CMS, AARP Public Policy Institute, KFF)
The ten drugs
The first round of Medicare price negotiation covers medications that between them touch an enormous number of Part D enrollees: Eliquis and Xarelto for blood clots and stroke prevention, Jardiance and Farxiga for type 2 diabetes and heart failure, Januvia for diabetes, Entresto for heart failure, Enbrel for rheumatoid arthritis and psoriasis, Imbruvica for certain blood cancers, Stelara for Crohn's and psoriasis, and the NovoLog and Fiasp insulins.
CMS reports the negotiated prices are meaningfully below what private Part D plans had been negotiating on their own — which is the whole argument for having Medicare do the negotiating, tested empirically for the first time.
Why the cap matters more than the discounts
The negotiated prices are the headline, but for an individual enrollee the cap is usually the bigger deal. The discounts help people on those specific ten drugs. The cap helps everyone on anything expensive, including the drugs nobody has negotiated yet.
Before the cap, a cancer diagnosis or a specialty biologic meant an open-ended annual liability. Now the worst year is bounded at $2,100 for covered drugs. For someone on a $10,000-a-year specialty medication, that is not a discount — it is the difference between a manageable expense and an impossible one.
The payment plan almost nobody has used
There is a second feature that gets almost no attention: Medicare enrollees can opt to spread their out-of-pocket drug costs across the year in monthly payments instead of absorbing them at the pharmacy counter.
This matters because the cap does not change when you pay. Someone who hits $2,100 in February still had to produce $2,100 in February. The smoothing option turns that into predictable monthly amounts. Uptake has been low, mostly because it requires opting in and nobody advertises it. If you take expensive medications, ask your Part D plan about it directly.
What to do at open enrollment
Part D plans change their formularies and tiers every year, and a plan that covered your drug well in 2026 may not in 2027. The annual exercise is unavoidable: check your actual medication list against each plan's formulary, not the plan's star rating or its premium.
The cap does not change that. What it changes is the downside if you get it wrong — which is now bounded rather than unlimited. For the full breakdown of how Parts A through D fit together, see our guide to Medicare, and for the enrollment deadlines that carry lifetime penalties, Medicare enrollment.